Regeneron investors urged to join class‑action lawsuit over alleged securities fraud during 2025‑26 stock period
Executive summary: Investors who purchased Regeneron stock between August 1 2025 and May 15 2026 are notified of an opportunity to lead a securities fraud class action lawsuit, with a deadline of September 14 2026 to apply as lead plaintiff. The lawsuit alleges misrepresentations about a Phase 3 clinical trial, potentially exposing Regeneron to significant legal costs and affecting investor confidence.
Who is involved: Regeneron Pharmaceuticals (NASDAQ: REGN), law firms Robbins Geller Rudman & Dowd LLP and Hagens Berman Sobol Shapiro LLP, and affected shareholders.
Likely next: Lead plaintiff motions must be filed by September 14 2026; the court will then consider class certification, after which settlement negotiations or trial proceedings may follow.
On September 3 2026, Robbins Geller Rudman & Dowd LLP announced that purchasers of Regeneron Pharmaceuticals stock between August 1 2025 and May 15 2026 may seek appointment as lead plaintiff in a securities fraud class action, with a filing deadline of September 14 2026. The alert follows a prior warning from Hagens Berman Sobol Shapiro LLP concerning disclosures about a Phase 3 clinical trial’s protocol and ultimate failure. The development highlights ongoing litigation risk for the biopharmaceutical firm and could affect its share price and legal expenses.
Timeline
- — REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit (PR Newswire)
- — REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure (PR Newswire)
Analysis — what this means
Likely next events
- Sep 14 2026: deadline for investors to file lead plaintiff applications for the REGN class action
- Oct 2026: expected court hearing on class certification of the REGN securities suit
- Q4 2026: potential settlement discussions if a lead plaintiff is appointed
Sectors affected
- biopharmaceuticals
- clinical trial disclosure compliance
Regulatory implications
- Possible enforcement of SEC Rule 10b-5 concerning material misstatements
- Increased oversight of pharmaceutical companies' clinical trial reporting
Historical parallels
- 2020 Biogen securities class action over aducanumab (ADUHELM) trial disclosures
- 2018 Bayer AG securities class action concerning Essure device safety disclosures
Key entities
Sources
Open the full interactive case file on Beyond →